Sanjaya Singh, Ph.D., is the Global Head of Janssen BioTherapeutics, the biotherapeutics engine of Janssen Research & Development. He is responsible for leading an organization of more than 300 employees in Spring House, PA, La Jolla, CA and Beerse, Belgium who are exploring new and innovative biologics platforms and realizing the potential of biopharmaceuticals for patients in need.
JBIO is focused on the discovery and development of monoclonal and multi-specific antibody technology, alternative scaffolds, peptides, and convergent products that transform and improve patients’ lives. In his role as head of JBIO, Sanjaya drives the strategy and overall vision to expand and apply this biotechnology expertise to a broad range of projects across Johnson & Johnson.
Sanjaya is an accomplished scientific and business leader with more than 25 years of industry and academic experience. Prior to joining Johnson & Johnson, he spent nine years at Boehringer Ingelheim, most recently serving as Vice President, Biotherapeutics Discovery. During his tenure, Sanjaya led a global team responsible for building a competitive and productive pre-clinical and clinical biotherapeutics pipeline. He has successfully led the identification of therapeutic targets in the field of immunomodulation and has developed biologic molecules in the fields of immunology, oncology, ophthalmology, cardio-metabolic and infectious disease.
In the realm of academia, Sanjaya held a faculty position in the Department of Molecular Biology at the Institute of Life Sciences in India. An author of numerous peer-reviewed articles, Sanjaya also is co-author on more than 25 patents.
Sanjaya earned a Ph.D. in Molecular Biology from Banaras Hindu University, Varanasi, Uttar Pradesh, India. He served as a Postdoctoral Fellow in the Department of Molecular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, and as a Research Associate in the Department of Biochemistry and Molecular Biology, also at MD Anderson Cancer Center in Texas.